Growth

Tesamorelin.

Available Variants

2 mg 5 mg 10 mg 20 mg

View lab reports Quality process

Research area: Growth

🛡️

For research purposes only. Not intended for use in humans or animals.

GH-axis research

About Tesamorelin

Tesamorelin is among the peptides researched in the context of the growth hormone (GH) axis. The chemical modification at the N-terminus protects tesamorelin from DPP-4 degradation, making it considerably more stable than unmodified GHRH.

Research Application

Studied in metabolic research on visceral fat tissue. It is the only GHRH-based peptide in this category with FDA approval (Egrifta) — though exclusively for HIV-associated lipodystrophy, not general body composition.

Important to know

Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.

Content 2 mg, 5 mg, 10 mg, 20 mg

Form Lyophilized powder

Category Growth

Purity & Identity see lab reports →

Sequence / Structure 44 amino acids – full GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus

Regulatory Status FDA approved since 2010 under the brand name Egrifta to reduce visceral fat in HIV-associated lipodystrophy; updated formulation Egrifta WR since 2024.

Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.

Research Overview

Numerous preclinical and some clinical studies exist on the GH axis, with evidentiary strength varying by substance.

Falutz J, et al. J Acquir Immune Defic Syndr. 2010;53(3):311–322. PMID 20101189
Stanley TL, et al. JAMA. 2014;312(4):380–389. PMID 25038357
Stanley TL, et al. Lancet HIV. 2019;6(12):e821–e830. PMID 31611038

References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.

Question about Tesamorelin?

We reply personally – via email or Telegram.

✉️ Email ✈️ Telegram

← Back to overview